This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

After NAC, the sentinel lymph node (SLN) identification rate is lower, and it has a higher false-negative rate than that in early-stage breast cancer. As appropriate SLN surgery directly affects the treatment and prognosis of patients undergoing NAC, evaluation to identify SLN using various methods is necessary.

This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

Inclusion Criteria:

• The patient with locally advanced breast cancer who achieved neoadjuvant chemotherapy
• Confirmed operability with imaging study after neoadjuvant chemotherapy
• Age over 20 years old
• ECOG Performance status : 0-2
• The patient with written informed consent form

Exclusion Criteria:

• The patient with previous ipsilateral breast cancer history
• The patinet with previous ipsilateral axillary surgical procedure (e.g. excisional or incisional biopsy, axillary dissection)
• The patient without neoadjuvant chemotherapy
• Inoperable imaging study after neoadjuvant chemotherapy
• Inflammatory breast cancer
• Pregnant patient

all IPD that underlie results in a publication

The data was generated on June 30, 2026, and can be provided for three years thereafter.

a publication of a paper about this study